Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 731

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 731
---
 6,200 |     |  7.3 | % |     |           6,520 |     |    5.2 | % |
| France  |     |  66,548,530 |     |           3,943 |     |  5.9 | % |     |           4,185 |     |    6.1 | % |
| UK      |     |  69,138,192 |     |           3,996 |     |  5.8 | % |     |           4,141 |     |    3.6 | % |
| Spain   |     |  47,910,526 |     |           5,141 |     | 10.7 | % |     |           5,576 |     |    8.5 | % |
| Italy   |     |  59,342,867 |     |           4,470 |     |  7.5 | % |     |           4,699 |     |    5.1 | % |
| Japan   |     | 123,753,041 |     |          11,005 |     |  8.9 | % |     |          10,543 |     |   -4.2 | % |
| Total   |     | 796,671,969 |     |          66,971 |     |  8.4 | % |     |          70,418 |     |    5.1 | % |

The total number of people with Diabetes in these seven countries in 2021 was estimated by the IDF as approximately 67 million with an estimated total growth of 5.1% by 2023 to approximately 70.4 million. Stem Cell Therapies Prices Over the past 3 years, drug manufacturers have disrupted the medical and prescription drug industries considerably with the rapid growth of cellular therapies. Often lifesaving, these therapies represent a promising new era for medical treatments in the US. However, the high cost and growing pipeline for cell therapies present considerable challenges for the US medical insurance market. As the number of approved cell therapies continues to grow, the impact on insurance claim activity is a paramount challenge for employers, insurers and reinsurers. The eligible population to receive these therapies is still relatively small, so while currently approved therapies have not yet become a significant percentage of overall US medical spend, claim frequency is slowly